INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia

Autores
Jameleddine, Mouna; Harzallah, Nabil; Grati, Hela; Odabachian Jebali, Marie Christine; Chemli, Jaafar; García Martí, Sebastián; Soto, Natalie; Pichón-Riviere, Andres; Hamouda, Chokri
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a costeffectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia’s compulsory insurance scheme. Our analysis was based on a probabilistic Markov cohort model that calculated the costs and quality-adjusted life years (QALY) associated with vemurafenib compared to the standard of care from a public payer perspective. The CEA indicated that vemurafenib provides a gain of 0.38 life years (1.78 vs. 1.4) for an incremental cost of USD 101,106.62 from the perspective of the main public payer (CNAM). This study revealed an incremental cost-effectiveness ratio (ICER) of 163,311.40 USD/QALY and 163,911.46 USD/QALY, respectively, from the CNAM and public health facilities’ perspectives. Vemurafenib cannot be considered cost-effective in terms of what has normally been considered a reasonable willingness to pay (WTP) in Tunisia. A significant price reduction would be necessary to bring the incremental cost-effectiveness ratio to an acceptable level.
Fil: Jameleddine, Mouna. The National Authority For Assessment And Accreditation; Túnez
Fil: Harzallah, Nabil. The National Authority For Assessment And Accreditation; Túnez
Fil: Grati, Hela. The National Authority For Assessment And Accreditation; Túnez
Fil: Odabachian Jebali, Marie Christine. The National Authority For Assessment And Accreditation; Túnez
Fil: Chemli, Jaafar. The National Authority For Assessment And Accreditation; Túnez
Fil: García Martí, Sebastián. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Soto, Natalie. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Pichón-Riviere, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Hamouda, Chokri. The National Authority For Assessment And Accreditation; Túnez
Materia
BRAF V600
TUNISIA
ADVANCED MELANOMA
COST UTILITY
COST-EFFECTIVENESS
HEALTH TECHNOLOGY ASSESSMENT
MARKET ACCESS
TARGETED THERAPY
VALUE-BASED PRICING
VEMURAFENIB
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/282061
Acceder
id CONICETDig_489c8b7ef9b5fd5eda3c391460ff0f28
oai_identifier_str oai:ri.conicet.gov.ar:11336/282061
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in TunisiaJameleddine, MounaHarzallah, NabilGrati, HelaOdabachian Jebali, Marie ChristineChemli, JaafarGarcía Martí, SebastiánSoto, NataliePichón-Riviere, AndresHamouda, ChokriBRAF V600TUNISIAADVANCED MELANOMACOST UTILITYCOST-EFFECTIVENESSHEALTH TECHNOLOGY ASSESSMENTMARKET ACCESSTARGETED THERAPYVALUE-BASED PRICINGVEMURAFENIBhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a costeffectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia’s compulsory insurance scheme. Our analysis was based on a probabilistic Markov cohort model that calculated the costs and quality-adjusted life years (QALY) associated with vemurafenib compared to the standard of care from a public payer perspective. The CEA indicated that vemurafenib provides a gain of 0.38 life years (1.78 vs. 1.4) for an incremental cost of USD 101,106.62 from the perspective of the main public payer (CNAM). This study revealed an incremental cost-effectiveness ratio (ICER) of 163,311.40 USD/QALY and 163,911.46 USD/QALY, respectively, from the CNAM and public health facilities’ perspectives. Vemurafenib cannot be considered cost-effective in terms of what has normally been considered a reasonable willingness to pay (WTP) in Tunisia. A significant price reduction would be necessary to bring the incremental cost-effectiveness ratio to an acceptable level.Fil: Jameleddine, Mouna. The National Authority For Assessment And Accreditation; TúnezFil: Harzallah, Nabil. The National Authority For Assessment And Accreditation; TúnezFil: Grati, Hela. The National Authority For Assessment And Accreditation; TúnezFil: Odabachian Jebali, Marie Christine. The National Authority For Assessment And Accreditation; TúnezFil: Chemli, Jaafar. The National Authority For Assessment And Accreditation; TúnezFil: García Martí, Sebastián. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Soto, Natalie. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Pichón-Riviere, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; ArgentinaFil: Hamouda, Chokri. The National Authority For Assessment And Accreditation; TúnezMultidisciplinary Digital Publishing Institute2024-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/282061Jameleddine, Mouna; Harzallah, Nabil; Grati, Hela; Odabachian Jebali, Marie Christine; Chemli, Jaafar; et al.; INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia; Multidisciplinary Digital Publishing Institute; Journal of Market Access & Health Policy; 12; 4; 10-2024; 294-3052001-6689CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2001-6689/12/4/23info:eu-repo/semantics/altIdentifier/doi/10.3390/jmahp12040023info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-03-31T15:02:26Zoai:ri.conicet.gov.ar:11336/282061instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-03-31 15:02:26.309CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
title INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
spellingShingle INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
Jameleddine, Mouna
BRAF V600
TUNISIA
ADVANCED MELANOMA
COST UTILITY
COST-EFFECTIVENESS
HEALTH TECHNOLOGY ASSESSMENT
MARKET ACCESS
TARGETED THERAPY
VALUE-BASED PRICING
VEMURAFENIB
title_short INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
title_full INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
title_fullStr INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
title_full_unstemmed INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
title_sort INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia
dc.creator.none.fl_str_mv Jameleddine, Mouna
Harzallah, Nabil
Grati, Hela
Odabachian Jebali, Marie Christine
Chemli, Jaafar
García Martí, Sebastián
Soto, Natalie
Pichón-Riviere, Andres
Hamouda, Chokri
author Jameleddine, Mouna
author_facet Jameleddine, Mouna
Harzallah, Nabil
Grati, Hela
Odabachian Jebali, Marie Christine
Chemli, Jaafar
García Martí, Sebastián
Soto, Natalie
Pichón-Riviere, Andres
Hamouda, Chokri
author_role author
author2 Harzallah, Nabil
Grati, Hela
Odabachian Jebali, Marie Christine
Chemli, Jaafar
García Martí, Sebastián
Soto, Natalie
Pichón-Riviere, Andres
Hamouda, Chokri
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BRAF V600
TUNISIA
ADVANCED MELANOMA
COST UTILITY
COST-EFFECTIVENESS
HEALTH TECHNOLOGY ASSESSMENT
MARKET ACCESS
TARGETED THERAPY
VALUE-BASED PRICING
VEMURAFENIB
topic BRAF V600
TUNISIA
ADVANCED MELANOMA
COST UTILITY
COST-EFFECTIVENESS
HEALTH TECHNOLOGY ASSESSMENT
MARKET ACCESS
TARGETED THERAPY
VALUE-BASED PRICING
VEMURAFENIB
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a costeffectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia’s compulsory insurance scheme. Our analysis was based on a probabilistic Markov cohort model that calculated the costs and quality-adjusted life years (QALY) associated with vemurafenib compared to the standard of care from a public payer perspective. The CEA indicated that vemurafenib provides a gain of 0.38 life years (1.78 vs. 1.4) for an incremental cost of USD 101,106.62 from the perspective of the main public payer (CNAM). This study revealed an incremental cost-effectiveness ratio (ICER) of 163,311.40 USD/QALY and 163,911.46 USD/QALY, respectively, from the CNAM and public health facilities’ perspectives. Vemurafenib cannot be considered cost-effective in terms of what has normally been considered a reasonable willingness to pay (WTP) in Tunisia. A significant price reduction would be necessary to bring the incremental cost-effectiveness ratio to an acceptable level.
Fil: Jameleddine, Mouna. The National Authority For Assessment And Accreditation; Túnez
Fil: Harzallah, Nabil. The National Authority For Assessment And Accreditation; Túnez
Fil: Grati, Hela. The National Authority For Assessment And Accreditation; Túnez
Fil: Odabachian Jebali, Marie Christine. The National Authority For Assessment And Accreditation; Túnez
Fil: Chemli, Jaafar. The National Authority For Assessment And Accreditation; Túnez
Fil: García Martí, Sebastián. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Soto, Natalie. Instituto de Efectividad Clínica y Sanitaria; Argentina
Fil: Pichón-Riviere, Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Epidemiología y Salud Pública. Instituto de Efectividad Clínica y Sanitaria. Centro de Investigaciones en Epidemiología y Salud Pública; Argentina
Fil: Hamouda, Chokri. The National Authority For Assessment And Accreditation; Túnez
description The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a costeffectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to price negotiation. This study was part of a broader HTA report that was prepared in response to a joint request from the regulatory authorities and the CNAM, Tunisia’s compulsory insurance scheme. Our analysis was based on a probabilistic Markov cohort model that calculated the costs and quality-adjusted life years (QALY) associated with vemurafenib compared to the standard of care from a public payer perspective. The CEA indicated that vemurafenib provides a gain of 0.38 life years (1.78 vs. 1.4) for an incremental cost of USD 101,106.62 from the perspective of the main public payer (CNAM). This study revealed an incremental cost-effectiveness ratio (ICER) of 163,311.40 USD/QALY and 163,911.46 USD/QALY, respectively, from the CNAM and public health facilities’ perspectives. Vemurafenib cannot be considered cost-effective in terms of what has normally been considered a reasonable willingness to pay (WTP) in Tunisia. A significant price reduction would be necessary to bring the incremental cost-effectiveness ratio to an acceptable level.
publishDate 2024
dc.date.none.fl_str_mv 2024-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/282061
Jameleddine, Mouna; Harzallah, Nabil; Grati, Hela; Odabachian Jebali, Marie Christine; Chemli, Jaafar; et al.; INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia; Multidisciplinary Digital Publishing Institute; Journal of Market Access & Health Policy; 12; 4; 10-2024; 294-305
2001-6689
CONICET Digital
CONICET
url http://hdl.handle.net/11336/282061
identifier_str_mv Jameleddine, Mouna; Harzallah, Nabil; Grati, Hela; Odabachian Jebali, Marie Christine; Chemli, Jaafar; et al.; INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia; Multidisciplinary Digital Publishing Institute; Journal of Market Access & Health Policy; 12; 4; 10-2024; 294-305
2001-6689
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2001-6689/12/4/23
info:eu-repo/semantics/altIdentifier/doi/10.3390/jmahp12040023
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1861214179050913792
score 12.822162

Publicaciones similares